
    
      Qualified participants who complete up to ~2 years of pembrolizumab treatment but progress
      after discontinuation may be eligible for a second course of pembrolizumab for up to ~1
      additional year, at the Investigator's discretion. Per protocol, response or progression
      during this second course will not count towards efficacy outcome measure and adverse events
      during this second course will not count towards safety outcome measures.
    
  